SLC16A3 and neoplasm: Mechanistically, ALKBH5 regulates the expression of Mct4/Slc16a3 and the content of lactate in the TME, thus suppressing the composition of tumor-infiltrating Treg cells as well as MDSCs, and finally regulating the response of PD-1 immunotherapy82.